KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Receivables - Net: 2014-2024

Historic Receivables - Net for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Dec 2024 value amounting to $36.5 million.

  • Aurinia Pharmaceuticals' Receivables - Net fell 15.81% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 15.81%. This contributed to the annual value of $36.5 million for FY2024, which is 51.70% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Receivables - Net stood at $36.5 million for FY2024, which was up 51.70% from $24.1 million recorded in FY2023.
  • Aurinia Pharmaceuticals' 5-year Receivables - Net high stood at $36.5 million for FY2024, and its period low was $13.5 million during FY2022.
  • For the 3-year period, Aurinia Pharmaceuticals' Receivables - Net averaged around $24.7 million, with its median value being $24.1 million (2023).
  • In the last 5 years, Aurinia Pharmaceuticals' Receivables - Net declined by 12.42% in 2022 and then surged by 78.44% in 2023.
  • Yearly analysis of 4 years shows Aurinia Pharmaceuticals' Receivables - Net stood at $15.4 million in 2021, then decreased by 12.42% to $13.5 million in 2022, then surged by 78.44% to $24.1 million in 2023, then soared by 51.70% to $36.5 million in 2024.